Kestra Private Wealth Services LLC increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 10.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,750 shares of the company's stock after buying an additional 1,058 shares during the quarter. Kestra Private Wealth Services LLC's holdings in Cencora were worth $2,989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently made changes to their positions in COR. Cornerstone Planning Group LLC increased its stake in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after buying an additional 48 shares during the period. Hoey Investments Inc. acquired a new position in shares of Cencora in the first quarter valued at approximately $28,000. Banque Transatlantique SA acquired a new position in shares of Cencora in the fourth quarter valued at approximately $29,000. Vermillion Wealth Management Inc. acquired a new position in shares of Cencora in the fourth quarter valued at approximately $38,000. Finally, Golden State Wealth Management LLC increased its stake in shares of Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.
Insider Buying and Selling at Cencora
In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares in the company, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,968 shares of the firm's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the transaction, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,125 shares of company stock worth $9,993,789. Company insiders own 10.80% of the company's stock.
Wall Street Analysts Forecast Growth
COR has been the topic of several analyst reports. Morgan Stanley set a $330.00 target price on Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Jefferies Financial Group upped their target price on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a report on Monday, June 30th. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Bank of America upped their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and an average price target of $309.83.
Check Out Our Latest Report on COR
Cencora Trading Down 0.8%
Shares of Cencora stock traded down $2.41 on Thursday, reaching $291.03. 349,826 shares of the company's stock were exchanged, compared to its average volume of 1,593,216. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35. The firm's 50-day moving average is $293.22 and its two-hundred day moving average is $273.46. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The company has a market capitalization of $56.41 billion, a P/E ratio of 33.75, a price-to-earnings-growth ratio of 1.45 and a beta of 0.57.
Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same period last year, the business earned $3.80 EPS. Cencora's quarterly revenue was up 10.3% compared to the same quarter last year. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
